NCT03986762View on ClinicalTrials.gov

Open Label Pharmaco- Magnetic Resonance Spectrography (MRS) Study of Clavulanic Acid

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 12, 2019

Primary Completion Date

December 20, 2019

Study Completion Date

December 20, 2019

Conditions
Cocaine Dependence, in RemissionCocaine Abuse, in RemissionCocaine-Related Disorders
Interventions
DRUG

Clavulanic Acid

\~10 days of Clavulanic Acid

Trial Locations (1)

19125

Episcopal Hospital Medical Arts Building, Philadelphia

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Temple University

OTHER

NCT03986762 - Open Label Pharmaco- Magnetic Resonance Spectrography (MRS) Study of Clavulanic Acid | Biotech Hunter | Biotech Hunter